CytomX Therapeutics, Inc.

CTMX

CytomX Therapeutics, Inc.

CTMX

Insider Sentiment (TTM):

Last Purchase:-Last Sale:2026-06-15Shares Purchased (TTM):0Shares Sold (TTM):294,480

Institutional Sentiment:

As of:2026-03-31Institutional Shares Owned:192,954,367Shares Outstanding:177,273,000Institutional Ownership Pct.:108.85%

Earnings Market Reaction:

Filing Date:2026-08-06Price on Filing Date:N/APrevious Close:N/A% Change:N/A

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Financial Statements

10‑Q10‑K

Values in Millions ($)	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30
Assets
Assets Current
Cash And Cash Equivalents At Carrying Value	17	29	13	34	49	48	38	41	43	36	17	26
Available For Sale Securities Debt Securities Curr…	313	318	124	109	109	32	63	77	94	114	157	168
Accounts Receivable Net Current	37	1	2	2	2	2	3	3	3	13	3	2
Prepaid Expense And Other Assets Current	4	6	5	4	5	5	4	3	3	4	5	5
Assets Current	373	353	144	149	165	87	107	124	143	167	183	201
Property Plant And Equipment Net	1	1	1	2	2	2	2	3	3	4	4	4
Indefinite Lived Intangible Assets Excluding Goodw…	0	0	0	0	1	1	1	1	1	1	1	1
Goodwill	1	1	1	1	1	1	1	1	1	1	1	1
Restricted Cash Noncurrent	1	2	2	1	1	1	1	1	1	1	1	1
Operating Lease Right Of Use Asset	5	2	3	5	6	7	8	9	10	11	12	13
Other Assets Noncurrent	0	0	0	0	0	0	0	0	0	0	0	0
Assets	381	359	152	158	175	98	121	139	159	185	202	221
Liabilities And Stockhold…
Liabilities Current
Accounts Payable Current	2	1	1	1	0	0	1	1	1	2	1	2
Accrued Liabilities Current	12	12	14	12	12	11	12	17	14	14	18	21
Operating Lease Liability Current	1	3	4	6	5	5	5	5	5	5	5	-
Contract With Customer Liability Current	24	18	27	22	22	33	67	96	124	124	132	124
Liabilities Current	40	34	47	41	39	50	86	119	143	145	156	147
Contract With Customer Liability Noncurrent	31	1	2	6	10	16	27	34	37	60	80	112
Operating Lease Liability Noncurrent	-	-	0	0	1	3	4	6	7	8	9	11
Other Liabilities Noncurrent	4	4	4	4	4	4	4	4	4	4	4	3
Liabilities	79	39	53	51	55	73	121	162	190	216	249	272
Stockholders Equity
Preferred Stock Value	0	0	0	0	0	0	0	0	0	0	-	-
Common Stock Value	0	0	0	0	0	0	0	0	0	0	0	0
Additional Paid In Capital	1,053	1,050	811	790	788	693	691	687	685	678	676	673
Accumulated Other Comprehensive Income Loss Net Of…	-0	0	0	0	0	-0	0	0	-0	-0	0	-0
Retained Earnings Accumulated Deficit	-751	-730	-712	-682	-668	-668	-692	-710	-716	-710	-723	-724
Stockholders Equity	302	320	99	107	120	25	-0	-23	-31	-32	-47	-51
Liabilities And Stockholders Equity	381	359	152	158	175	98	121	139	159	185	202	221
Convertible Preferred Stock	-	-	0	-	-	-	0	-	-	-	0	0
Common Stock Par Or Stated Value Per Share	-	-	0	-	-	-	0	-	-	-	0	-
Common Stock Shares Authorized	-	-	300	-	-	-	150	-	-	-	150	-
Common Stock Shares Issued	-	-	170	-	-	-	80	-	-	-	67	-
Shares Outstanding	-	-	170	-	-	-	80	-	-	-	67	-

Subscribe to unlock 17+ years of financial data, unlimited metrics, and saved tables

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, and saved tables

Start free trial

Custom Table

10‑Q10‑K

0/5

Search a metric to start building a table

Subscribe to unlock 17+ years of financial data, unlimited metrics, transformations, and saved visuals

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, transformations, and saved visuals

Start free trial

Interactive Financial Visualizations

10‑Q10‑K

Stock Price:

OnOff

Transformations:

0/1

Search a metric to start building a visual

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Earnings Market Reaction

10‑Q10‑K

Fiscal Year	Q1 1 Month	Q1 2 Month	Q1 3 Month	Q2 1 Month	Q2 2 Month	Q2 3 Month	Q3 1 Month	Q3 2 Month	Q3 3 Month	Q4 1 Month	Q4 2 Month	Q4 3 Month
2026	-10.00%	-15.00%	-19.00%	-	-	-	-	-	-	-	-	-
2025	23.94%	17.37%	10.33%	-2.86%	38.10%	55.24%	2.15%	4.77%	32.22%	-34.96%	-41.04%	-55.56%
2024	-59.43%	-70.88%	-64.20%	0.00%	1.69%	-12.71%	6.00%	7.00%	-10.90%	1.78%	15.07%	261.43%
2023	-	-	-	-11.24%	-23.67%	-36.69%	10.16%	21.09%	24.22%	-17.93%	76.49%	-32.27%
Earnings Market Reaction data beyond 3 years is for subscribers only. Unlock the full earnings market reaction history Start 7-day free trial

Subscribe to unlock 17+ years of financial data and 90+ calculated metrics

Start 7-day free trial

Subscribe to unlock 17+ years of data and 90+ calculated metrics

Start free trial

Performance and Valuation Metrics

Rows marked with a lock icon are subscribers only — subscribe to unlock 90+ calculated metrics and 17+ years of history.

Metrics	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30
Liquidity Ratios
Current Ratio	9.36	10.38	3.09	3.64	4.20	1.73	1.25	1.04	1.00	1.16	1.17	1.37
Quick Ratio	9.25	10.21	2.98	3.54	4.08	1.63	1.21	1.01	0.98	1.13	1.14	1.34
Working Capital	333.29M	319.07M	97.31M	108.19M	125.40M	36.43M	21.53M	4.95M	222.00K	22.71M	27.02M	54.41M
Leverage & Debt
Debt to Equity	0.26	0.12	0.53	0.47	0.46	2.93	-265.33	-6.93	-6.10	-6.83	-5.25	-5.32
Debt Ratio	0.21	0.11	0.35	0.32	0.32	0.75	1.00	1.17	1.20	1.17	1.24	1.23
Efficiency & Turnover
Asset Turnover TTM	0.07	0.16	0.56	0.76	0.84	1.04	0.86	0.70	0.65	0.57	0.44	0.42
Days Sales Outstanding TTM	392.51	13.36	12.25	8.00	6.01	18.72	8.64	8.32	7.14	21.85	71.07	7.96
Receivables Turnover TTM	0.93	27.32	29.79	45.63	60.77	19.50	42.27	43.88	51.12	16.71	5.14	45.86
Per Share Metrics
Diluted EPS TTM	-0.38	-0.35	-0.15	0.17	0.37	0.48	0.38	0.16	0.13	0.20	-0.01	-0.13
Free Cash Flow Per Share TTM	-0.38	-0.45	-0.55	-0.44	-0.60	-0.94	-1.02	-1.04	-1.02	-1.13	-0.77	-0.45
Dividend Per Share TTM	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Margin Metrics
Operating Profit Margin TTM	-476.19%	-181.92%	-29.35%	20.46%	30.56%	24.37%	18.10%	5.30%	4.79%	9.08%	-6.41%	-16.24%
Net Profit Margin TTM	-451.62%	-174.84%	-26.73%	24.66%	34.01%	28.19%	23.08%	10.92%	9.27%	13.87%	-0.56%	-10.75%
Growth Metrics
Net Revenue Growth (1Y)	-87.03%	-75.91%	-44.82%	-10.26%	18.01%	23.81%	36.45%	33.66%	50.41%	76.24%	90.38%	361.96%
Net Income Growth (1Y)	-272.26%	-249.37%	-163.92%	102.59%	332.83%	151.64%	-5,700.88%	-235.83%	-126.25%	-123.40%	-99.43%	-93.17%
EPS Growth (1Y)	-201.56%	-173.41%	-139.13%	4.48%	184.63%	136.93%	-4,995.72%	-228.87%	-120.57%	-118.90%	-99.49%	-94.42%
Valuation Metrics
P/E TTM	-9.93	-13.41	-28.85	18.79	6.11	1.33	2.73	7.26	9.34	10.82	-201.06	-10.23
P/B TTM	2.72	2.60	5.93	4.90	2.44	2.21	-190.73	-4.28	-3.32	-5.64	-2.41	-2.03
P/S TTM	44.86	23.44	7.71	4.63	2.08	0.38	0.63	0.79	0.87	1.50	1.13	1.10
Market Cap	821.02M	833.18M	587.61M	526.36M	293.00M	55.41M	86.97M	100.41M	103.55M	178.82M	114.40M	104.14M
Enterprise Value	803.80M	804.36M	574.94M	492.18M	243.96M	7.81M	48.92M	59.83M	60.31M	142.64M	97.23M	78.12M
Calculated Values
Free Cash Flow TTM	-82.74M	-80.45M	-76.06M	-72.61M	-77.68M	-81.54M	-86.54M	-88.78M	-86.29M	-92.34M	-56.88M	-36.22M
Net Debt	-17.22M	-28.83M	-12.67M	-34.19M	-49.04M	-47.60M	-38.05M	-40.58M	-43.25M	-36.19M	-17.17M	-26.02M
Per-Share and Margin
EPS TTM
Adjusted EPS TTM
Cash Flow Per Share TTM
Pretax Margin TTM
Stock Comp to Revenue TTM
Turnover Ratios and Averages
Average Assets
Average Equity
Average Inventory
Average Receivables
Average Accounts Payables
Inventory Turnover TTM
Payables Turnover TTM
Days Inventory Outstanding TTM
Days Payables Outstanding TTM
Cash Conversion Cycle TTM
Working Capital to Revenue
Deferred Revenue to Revenue
Growth Rates
Total Assets Growth (1Y)
Total Assets Growth (3Y)
Total Assets Growth (5Y)
Dividends Paid Growth (1Y)
Dividends Paid Growth (3Y)
Dividends Paid Growth (5Y)
EPS Growth (3Y)
EPS Growth (5Y)
Net Income Growth (3Y)
Net Income Growth (5Y)
Net Profit Margin Growth (1Y)
Net Profit Margin Growth (3Y)
Net Profit Margin Growth (5Y)
Net Revenue Growth (3Y)
Net Revenue Growth (5Y)
Deferred Revenue Growth (1Y)
Retained Earnings Growth (1Y)
Credit, Liquidity, Returns, Payout
Cash Ratio
Net Working Capital
Debt to EBITDA TTM
Net Debt to EBITDA TTM
Net Debt to Equity
Altman A
Altman B
Altman C
Altman D
Altman E
Altman Z-Score
ROA TTM
ROE TTM
NOPAT TTM
ROIC TTM
Effective Tax Rate TTM
Payout Ratio TTM
Dilution Ratio
Retained Earnings to Equity
Treasury Stock to Equity
Treasury Stock Change (1Y)
Accrued to Current Liabilities
NCAV
NCAV Per Share TTM
Valuation Ratios
P/CF TTM
Dividend Yield TTM
Free Cash Flow Yield TTM
EV EBITDA TTM
EV EBIT TTM
Stock Compensation TTM
Adjusted Net Income TTM
Billings TTM
Total Debt
Invested Capital

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Insider Transactions

2026-06-15Sale

Owner: Ogden, Christopher

Title: Chief Financial Officer

Shares: 1,624

Price/Share: $3.05

Value: $4,953.20

Shares Owned: 295,324

Relationship: Officer

Ownership: Direct

2026-03-17Sale

Owner: Belvin, Marcia

Title: SVP, Chief Scientific Officer

Shares: 31,492

Price/Share: $6.42

Value: $202,178.64

Shares Owned: 300,760

Relationship: Officer

Ownership: Direct

2026-03-17Sale

Owner: Mccarthy, Sean A.

Title: CEO

Shares: 118,969

Price/Share: $6.42

Value: $763,780.98

Shares Owned: 1,078,922

Relationship: Director,Officer

Ownership: Direct

2026-03-17Sale

Owner: Ogden, Christopher

Title: Chief Financial Officer

Shares: 19,323

Price/Share: $6.42

Value: $124,053.66

Shares Owned: 296,948

Relationship: Officer

Ownership: Direct

2026-03-17Sale

Owner: Chu, Yu-Waye

Title: Chief Medical Officer

Shares: 21,279

Price/Share: $6.42

Value: $136,611.18

Shares Owned: 189,446

Relationship: Officer

Ownership: Direct

Filed Date	Owner	Relationship	Title	Ownership	Purchase/Sale	No. Shares	Price Per Share	Value	Shares Owned	Document Type
2026-06-15	Ogden, Christopher	Officer	Chief Financial Officer	Direct	Sale	1,624	3.05	$4,953.20	295,324	4
2026-03-17	Belvin, Marcia	Officer	SVP, Chief Scientific Officer	Direct	Sale	31,492	6.42	$202,178.64	300,760	4
2026-03-17	Mccarthy, Sean A.	Director,Officer	CEO	Direct	Sale	118,969	6.42	$763,780.98	1,078,922	4
2026-03-17	Ogden, Christopher	Officer	Chief Financial Officer	Direct	Sale	19,323	6.42	$124,053.66	296,948	4
2026-03-17	Chu, Yu-Waye	Officer	Chief Medical Officer	Direct	Sale	21,279	6.42	$136,611.18	189,446	4
2025-11-06	Mccarthy, Sean A.	Director,Officer	CEO	Direct	Sale	101,793	4.54	$462,140.22	987,891	4
2025-06-16	Mccarthy, Sean A.	Director,Officer	CEO	Direct	Sale	55,511	2.69	$149,324.59	1,089,684	4
2025-06-16	Belvin, Marcia	Officer	SVP, Chief Scientific Officer	Direct	Sale	13,884	2.69	$37,347.96	272,252	4
2025-06-16	Ogden, Christopher	Officer	Chief Financial Officer	Direct	Sale	10,614	2.69	$28,551.66	226,271	4
2025-03-18	Ogden, Christopher	Officer	Chief Financial Officer	Direct	Sale	8,551	0.60	$5,130.60	201,026	4
2025-03-18	Chu, Yu-Waye	Officer	Chief Medical Officer	Direct	Sale	4,025	0.60	$2,415.00	135,725	4
2025-03-18	Belvin, Marcia	Officer	SVP, Chief Scientific Officer	Direct	Sale	19,512	0.60	$11,707.20	248,636	4
2025-03-18	Rowland, Lloyd A	Officer	General Counsel	Direct	Sale	10,203	0.60	$6,121.80	120,594	4
2025-03-18	Mccarthy, Sean A.	Director,Officer	CEO	Direct	Sale	37,656	0.60	$22,593.60	995,195	4
2024-08-20	Landau, Jeffrey B	Officer	Chief Business Officer	Direct	Sale	4,181	1.23	$5,142.63	119,056	4
2024-08-20	Belvin, Marcia	Officer	SVP, Chief Scientific Officer	Direct	Sale	4,181	1.23	$5,142.63	175,648	4
2024-08-20	Mccarthy, Sean A.	Director,Officer	CEO	Direct	Sale	13,898	1.23	$17,094.54	657,851	4
2024-08-20	Ogden, Christopher	Officer	Chief Financial Officer	Direct	Sale	1,984	1.23	$2,440.32	108,077	4
2024-08-20	Rowland, Lloyd A	Officer	General Counsel	Direct	Sale	4,181	1.23	$5,142.63	130,797	4
2024-03-19	Landau, Jeffrey B	Officer	Chief Business Officer	Direct	Sale	6,562	2.09	$13,714.58	110,060	4
2024-03-19	Ogden, Christopher	Officer	SVP, Finance and Accounting	Direct	Sale	2,971	2.09	$6,209.39	85,686	4
2024-03-19	Mccarthy, Sean A.	Director,Officer	CEO	Direct	Sale	20,223	2.09	$42,266.07	524,481	4
2024-03-19	Belvin, Marcia	Officer	SVP, Chief Scientific Officer	Direct	Sale	12,795	2.09	$26,741.55	168,579	4
2024-03-19	Rowland, Lloyd A	Officer	General Counsel	Direct	Sale	5,268	2.09	$11,010.12	117,728	4
2023-12-20	Ogden, Christopher	Officer	SVP, Finance and Accounting	Direct	Sale	1,990	1.38	$2,746.20	48,657	4
2023-12-20	Belvin, Marcia	Officer	SVP, Chief Scientific Officer	Direct	Sale	4,077	1.38	$5,626.26	155,124	4
2023-12-20	Mccarthy, Sean A.	Director,Officer	CEO	Direct	Sale	13,551	1.38	$18,700.38	454,704	4
2023-12-20	Landau, Jeffrey B	Officer	Chief Business Officer	Direct	Sale	4,077	1.38	$5,626.26	86,622	4
2023-12-20	Rowland, Lloyd A	Officer	General Counsel	Direct	Sale	4,077	1.38	$5,626.26	97,996	4
2023-09-22	Belvin, Marcia	Officer	SVP, Chief Scientific Officer	Direct	Sale	4,119	1.30	$5,354.70	147,951	4
2023-09-22	Rowland, Lloyd A	Officer	General Counsel	Direct	Sale	5,486	1.30	$7,131.80	80,609	4
2023-09-22	Landau, Jeffrey B	Officer	Chief Business Officer	Direct	Sale	4,119	1.30	$5,354.70	76,379	4
2023-09-22	Mccarthy, Sean A.	Director,Officer	CEO	Direct	Sale	14,601	1.30	$18,981.30	430,755	4
Additional insider transactions are for subscribers only. Unlock the complete Form 4 filing history Start 7-day free trial

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Institutional Ownership

No data available for chart

2026-03-31

108.85%

Inst. Shares: 192,954,367

Shares Outstanding: 177,273,000

2025-12-31

103.66%

Inst. Shares: 142,978,769

Shares Outstanding: 137,935,873

2025-09-30

82.60%

Inst. Shares: 136,288,091

Shares Outstanding: 165,004,291

2025-06-30

101.46%

Inst. Shares: 130,959,329

Shares Outstanding: 129,075,546

2025-03-31

47.27%

Inst. Shares: 41,180,446

Shares Outstanding: 87,121,502

Date	Institutional Shares Owned	Shares Outstanding	Institutional Ownership %
2026-03-31	192,954,367	177,273,000	108.85%
2025-12-31	142,978,769	137,935,873	103.66%
2025-09-30	136,288,091	165,004,291	82.60%
2025-06-30	130,959,329	129,075,546	101.46%
2025-03-31	41,180,446	87,121,502	47.27%
2024-12-31	43,282,734	84,439,303	51.26%
2024-09-30	47,670,879	85,093,227	56.02%
2024-06-30	47,655,298	84,880,632	56.14%
2024-03-31	40,072,222	82,029,466	48.85%
2023-12-31	28,446,100	73,808,237	38.54%
2023-09-30	28,711,432	80,731,951	35.56%
2023-06-30	29,250,820	66,536,202	43.96%
Additional institutional holders are for subscribers only. Unlock the complete Form 13F ownership history Start 7-day free trial

CytomX Therapeutics, Inc. (CTMX) — SEC Financial Statements & Analysis

CytomX Therapeutics, Inc. (CTMX) is a pharmaceutical preparations company, incorporated in DE. CytomX Therapeutics, Inc. trades on Nasdaq as: CTMX. Based on its latest SEC filing (Form 10-Q, period ending 2026-06-30), CytomX Therapeutics, Inc. reported a -87.03% year-over-year revenue growth, a Debt-to-Equity ratio of 0.26x, a Price-to-Sales (P/S) ratio of 44.86x (TTM), a Price-to-Book (P/B) ratio of 2.72x (TTM), at a market cap of $821.02M. Figures below are sourced from SEC EDGAR, as-filed.

Net Revenue TTM Growth 1Y: -87.03%
Debt To Equity: 0.26x
P/S TTM: 44.86x
P/B TTM: 2.72x
Market Cap: $821.02M

Data as of 2026-06-30 · Source: SEC EDGAR

Frequently Asked Questions

What industry is CytomX Therapeutics, Inc. in?

CytomX Therapeutics, Inc. (CTMX) operates in the Pharmaceutical Preparations industry.

What is CTMX's market cap?

CytomX Therapeutics, Inc. (CTMX) has a market capitalization of $821.02M as of 2026-06-30.

What exchange does CTMX trade on?

CytomX Therapeutics, Inc. (CTMX) trades on the Nasdaq.

Where is CytomX Therapeutics, Inc. incorporated?

CytomX Therapeutics, Inc. is incorporated in DE.